Board of directors
|
|
Kerstin Valinder Strinnholm Executive Chairman Born 1960. Active in the company since 2022. Kerstin holds a degree in Journalism från the University of Gothenburg, Sweden. Kerstin brings more than 30 years of international pharma experience. She has worked in leading positions at e.g. AstraZeneca and Nycomed/Takeda, with a primary focus on commercial and business strategic areas. Currently Kerstin acts as business advisor at transactions within the life science fied and is also non-executive member of the boards of Camurus AB, Promore Pharma AB, Immedica AB and BioServo Technologies AB. Shareholding: 89 957 shares. Independent in relation to the company and the owners. |
|
|
Anders Lundmark
Born 1958. Member since 2022. Amders holds a Master of Science in Business Administration and Economics from the Uppsala University. Anders has 25 years of experience years as a CFO along with growth-related operational responsibilities. He has worked extensively under private equity regimes as well as in both listed and privately held companies. Amongst them, he has been the CFO of Phadia Group, Iggesund Paperboard, Trelleborg Industries and Observer/Cision. He is currently the Chairman of Bioservo Technologies AB and a member of the Board of Directors of Tellacq Group AB, Secure Appbox AB and Antrad Medical AB.
Shareholding: 1 246 057 shares. Independent in relation to the company and the owners. |
|
|
Mattias Klintemar Born 1967. Member since 2015. Mattias Klintemar represents Östersjöstiftelsen and has extensive experiences from leadership roles within the finance and technology sector, e.g.as CEO at Morphic Technologies AB, CFO at Hexaformer, equity analyst and corporate finance associate at ABG Sundal Collier and auditor and consultant at former Arthur Andersen. He is Investment director at Östersjöstiftelsen, Chairman of the Board of Luci Intressenter AB, Board member of Cereal Base CEBA AB, OncoZenge AB, Biosergen AB, Oatly Group AB (publ), Klintemar Konsult AB, Palette Life Science AB, Oatly EMEA AB, MLJK Konsult AB and Havrekärnan AB. Shareholding: 69 347 shares. Independent in relation to the company. |
 |
Nikolaj Sørensen Born 1972. Board members since 2021. Nikolaj Sörensen has more than 20 years of experience from the life science and the pharmaceutical industry in Sweden and abroad. Nikolaj today serves as President and CEO of Orexo AB and Member of the Board at Bioservo Technologies AB. Previous appointments includes senior management positions at Pfizer and as management consultant at the Boston Consulting Group (BCG). Nikolaj has a M.Sc. in International Business from Copenhagen Business School. Shareholding: 75 218 shares. independent from the company and the owners. |
Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.